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Given the multiplicity of anti-inﬂ   ammatory actions of 
activated protein C (APC), it is perhaps not surprising 
that APC would be eﬀ  ective in reducing the severity of 
lung injury produced by the use of large tidal volumes 
during mechanical ventilation. In this issue of Critical 
Care, Maniatis and colleagues [1] provide data showing 
that inhaled APC is protective against ventilator-induced 
lung injury (VILI). Th  e use of inhaled APC in these 
studies is an intriguing use of this agent and would be 
expected to target its eﬀ  ects to the airways and alveoli 
aﬀ   ected by VILI while minimizing systemic eﬀ  ects. 
Unfor  tunately, the present study does not provide any 
information about circulating coagulation parameters or 
about potential leakage of the inhaled APC into the 
systemic circulation, so it is unknown at present whether 
the beneﬁ  cial eﬀ  ects found in these experiments are due 
purely to the pulmonary eﬀ   ects of APC or whether 
inhaled APC can gain access to the circulation, thereby 
exerting its eﬀ  ects on the lungs and other organs.
In addition to its eﬀ  ects on coagulation cascades, APC 
has been shown to have a number of actions that may 
contribute to reducing inﬂ   ammation in the setting of 
sepsis or acute lung injury. For example, APC has potent 
anti-apoptotic eﬀ   ects on endothelial cells that remain 
even when modiﬁ  ed forms of APC that lack anti-coagu-
lant properties are used [2]. Interaction between APC 
and the endothelial protein C receptor, which is actually a 
misnomer since this receptor is also found on other cell 
populations, including neutrophils and mononuclear 
cells, results in diminished migration toward inﬂ  amma-
tory gradients [3]. In human studies in which lipopoly-
saccharide (LPS) was instilled into airways, there were 
decreased numbers of neutrophils in the airways among 
the volunteers randomly assigned to infusions of APC 
[3]. Recent data have shown that APC cleaves histones 
released by dying cells, diminishing the damage to 
endothelial cells and inﬂ  ammatory responses initiated by 
exposure to histones [4]. Finally, interaction of APC with 
protease-activated receptor-1 can diminish the activation 
of macrophages and other cell populations [5-7].
While the authors of this article hypothesize that the 
beneﬁ  cial actions of inhaled APC in VILI result from 
inhibition of activation of the extracellular-regulated 
kinase (ERK) pathway, this potential mechanism is not 
directly explored. Rather, diminished ERK activation is 
shown in lung homogenates and in cultured lung 
epithelial cells after treatment with APC. However, it 
remains unclear whether the decrease in ERK activation 
is the cause of the beneﬁ  cial eﬀ  ects of APC or rather is 
simply a reﬂ   ection of the decrease in inﬂ  ammation 
produced by APC treatment. Additional experiments in 
which ERK was speciﬁ  cally inhibited would be necessary 
to determine the importance of this signaling pathway in 
modulating the eﬀ  ects of APC in VILI.
Several previous studies have shown that inhaled APC 
reduces lung injury and inﬂ  ammation in models of LPS-
induced lung injury [8-10]. In those studies, despite 
decreases in histologic indices of lung injury, neutrophil 
numbers and concentrations of proinﬂ  ammatory 
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treatment. In contrast, in at least one study, inhaled APC 
did reduce the severity of coagulation abnormalities in the 
lungs [10]. Such results suggest that the beneﬁ  cial eﬀ  ects 
of inhaled APC may result from reversing altera  tions in 
coagulation and ﬁ  brinolysis, which are almost ubiquitous 
ﬁ  ndings in acute lung injury, or possibly from diminishing 
the enhanced apoptosis of epithelial and other cell 
populations which accompanies acute lung injury.
In the present experiments, treatment with APC was 
started before the initiation of injurious ventilation. 
Th  ere  fore, it remains unknown at present whether 
inhaled APC would be beneﬁ   cial if initiated after the 
lungs have been exposed to large tidal volumes, an 
important clinical issue. Additionally, low-tidal-volume 
ventilation has become the standard of care in critically 
ill patients because of studies showing that its use 
improves outcome, including diminishing mortality, in 
patients with acute lung injury and also is likely to 
prevent the development of lung injury when used as the 
initial mode of ventilation [11-14]. Th  erefore,  the 
clinically relevant questions now become whether 
inhaled APC can diminish the severity of lung injury 
when used in conjunction with low-tidal-volume ventila-
tion in the presence of acute lung injury due to sepsis or 
other etiologies and whether inhaled APC can prevent or 
minimize primary or secondary lung damage when low 
tidal volumes are used for mechanical ventilation.
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